Antibody-secreting cells (ASCs) are key components of adaptive immunity and include both short-lived plasmablasts, which are generated rapidly following immunization, and long-lived plasma cells, which are responsible for sustained antibody production. Plasmablasts are transiently detectable in peripheral blood and secondary lymphoid organs, reaching peak frequencies at defined time points following immunization that vary according to the vaccine formulation and host species (typically days 4–5 in rhesus macaques and approximately day 7 in humans). In contrast, mature plasma cells are long-lived and primarily reside within secondary lymphoid tissues and the bone marrow (BM). An effective vaccine should elicit both robust humoral and cell-mediated immune responses. Measurement of recall responses, reflected by the rapid expansion of plasmablasts in peripheral blood mononuclear cells (PBMCs) following booster immunization, provides valuable insight into the magnitude of the vaccine-induced immune response. The overall goal of this protocol is to provide a robust method for quantifying early plasmablast and long-lived plasma cell responses following Env-specific immunization in rhesus macaques.
In an enzyme-linked immunospot (ELISpot) assay, ASCs are cultured in polyvinylidene fluoride (PVDF) or mixed cellulose ester (MCE) membrane-bottom 96-well plates coated with antigen (Ag), allowing viable cells to secrete proteins that are captured directly on the membrane surface. The captured proteins are subsequently detected using antibodies in a conventional sandwich immunoassay format. In chromogenic ELISpot assays, spots are generated through the conversion of the substrate 3-amino-9-ethylcarbazole (AEC) by horseradish peroxidase (HRP) into an insoluble colored precipitate, enabling visualization and enumeration of individual ASCs. ELISpot offers several important advantages, including the ability to detect antigen-specific responses ex vivo, highly sensitive functional assessment of individual immune cells, and quantitative monitoring of T- and B-cell immune responses in both preclinical and clinical studies1,2,3.
Here, a B-cell ELISpot protocol is described for quantifying total and antigen-specific IgG, IgM, and IgA ASCs in PBMCs and BM cells from rhesus macaques. The protocol details all critical steps, including plate coating, blocking, cell seeding, assay development, spot enumeration, and data analysis, to characterize the kinetics of total and Env-specific plasmablast and plasma cell responses. This method provides a reproducible approach for evaluating and comparing the immunogenicity of different antigen and adjuvant formulations in preclinical vaccine studies and supports the optimization of vaccine strategies for subsequent clinical translation.